 The day dawned as an MA Thursday for the biotech sector, as a slew of deals of varied sizes were announced, with Gilead Sciences, Inc. NASDAQ: GILD and Aytu BioScience, Inc. NASDAQ: AYTU in the mix. Gilead Snaps Up Germany Drug Company In 1B Deal: Large-cap pharma Gilead announced Thursday an agreement to acquire German biotech MYR, which focuses on therapeutics for chronic hepatitis delta virus, or HDV, for an upfront payment of 1.15 billion euros 1.39 billion in cash, payable upon closing of the transaction, and 300 million euros 363 million in potential future milestone payments. 